[go: up one dir, main page]

BRPI1008936B8 - método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano - Google Patents

método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano

Info

Publication number
BRPI1008936B8
BRPI1008936B8 BRPI1008936A BRPI1008936A BRPI1008936B8 BR PI1008936 B8 BRPI1008936 B8 BR PI1008936B8 BR PI1008936 A BRPI1008936 A BR PI1008936A BR PI1008936 A BRPI1008936 A BR PI1008936A BR PI1008936 B8 BRPI1008936 B8 BR PI1008936B8
Authority
BR
Brazil
Prior art keywords
prognosis
diagnosis
vitro method
fibrosis
predisposition
Prior art date
Application number
BRPI1008936A
Other languages
English (en)
Inventor
Dessein Alain
Chevillard Christophe
Arnaud Violaine
Original Assignee
Inst Nat Sante Rech Med
Univ De La Mediterranee
Univ Aix Marseille
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ De La Mediterranee, Univ Aix Marseille filed Critical Inst Nat Sante Rech Med
Publication of BRPI1008936A2 publication Critical patent/BRPI1008936A2/pt
Publication of BRPI1008936B1 publication Critical patent/BRPI1008936B1/pt
Publication of BRPI1008936B8 publication Critical patent/BRPI1008936B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

método in vitro para detectar pré-disposição, diagnóstico e / ou prognóstico de fibrose e método de seleção de um composto terapêutico. a presente invenção revela a identificação de um locus do gene de suceptibilidade á fribose, o locus do gene ctgf,que pode ser usado para detectar predisposto a, dignóstico e prognóstico de fibrose, bem como para o rastreamento de medicamentos terapeuticamente ativos. a invenção reside, em uma amostra de indivíduo de presença de uma alteração no locus do gene ctgf, a presença da dita alteração sendo indicativa da presença ou predisposto á fibrose.
BRPI1008936A 2009-02-19 2010-02-18 método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano BRPI1008936B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09305159A EP2221387A1 (en) 2009-02-19 2009-02-19 Fibrosis susceptibility gene and uses thereof
EP093051597 2009-02-19
PCT/EP2010/052048 WO2010094740A1 (en) 2009-02-19 2010-02-18 Fibrosis susceptibility gene and uses thereof

Publications (3)

Publication Number Publication Date
BRPI1008936A2 BRPI1008936A2 (pt) 2016-10-11
BRPI1008936B1 BRPI1008936B1 (pt) 2021-04-06
BRPI1008936B8 true BRPI1008936B8 (pt) 2021-07-27

Family

ID=40568438

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008936A BRPI1008936B8 (pt) 2009-02-19 2010-02-18 método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano

Country Status (8)

Country Link
US (2) US9297044B2 (pt)
EP (2) EP2221387A1 (pt)
JP (2) JP5837825B2 (pt)
KR (1) KR101748679B1 (pt)
CN (2) CN102325904B (pt)
BR (1) BRPI1008936B8 (pt)
CA (1) CA2752802C (pt)
WO (1) WO2010094740A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012085217A1 (en) * 2010-12-22 2012-06-28 Universite De La Mediterranee (Aix-Marseille Ii) A diagnostic method for dementias
CN104302780B (zh) * 2011-08-05 2017-04-12 艾克斯-马赛大学 纤维变性易感性il22ra2基因及其用途
ES2422874B1 (es) * 2012-03-12 2014-07-15 Universidad Autnoma De Madrid Método in vitro de pronóstico de fibrosis hepática grave
DK3607065T5 (da) * 2017-04-06 2024-09-02 Complete Omics Int Inc Fremgangsmåde og kit til konstruktion af nukleinsyrebibliotek
EP3425056A1 (en) * 2017-07-07 2019-01-09 Genepred Biotechnologies Method for prognosing fibrosis progression
JP7476179B2 (ja) * 2018-10-02 2024-04-30 テトラ ラバル ホールディングス アンド ファイナンス エス エイ 包装ユニットの製造プロセスを制御するシステム
WO2020074727A1 (en) 2018-10-11 2020-04-16 Genepred Biotechnologies Method for detecting fibrosis especially keloid
CN111073884A (zh) * 2020-02-14 2020-04-28 昆明理工大学 提高非编码区域距离＜50bp的SNP中具有功能效应的SNP位点检测准确率的方法
WO2025114508A1 (en) * 2023-11-30 2025-06-05 Universität Heidelberg Method for predicting the risk of a cancer subject for developing radiation-induced skin fibrosis

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770209A (en) 1991-08-30 1998-06-23 University Of South Florida Acceleration of wound healing using connective tissue growth factor
EP0730663B1 (en) 1993-10-26 2003-09-24 Affymetrix, Inc. Arrays of nucleic acid probes on biological chips
US20030092019A1 (en) * 2001-01-09 2003-05-15 Millennium Pharmaceuticals, Inc. Methods and compositions for diagnosing and treating neuropsychiatric disorders such as schizophrenia
JP4226471B2 (ja) * 2001-09-18 2009-02-18 ファイブローゲン、インコーポレーテッド 結合組織増殖因子の分析方法
US7405274B2 (en) * 2003-06-04 2008-07-29 Fibrogen, Inc. Connective tissue growth factor antibodies
GB0326780D0 (en) 2003-11-18 2003-12-24 Imp College Innovations Ltd Biological materials and uses thereof
AU2007328206B2 (en) * 2006-12-04 2013-08-01 Promedior, Inc. Conjoint therapy for treating fibrotic diseases
WO2011138370A1 (en) 2010-05-04 2011-11-10 Universite De La Mediterranee (Aix-Marseille Ii) Antiviral treatment susceptibility gene and uses thereof
CN104302780B (zh) 2011-08-05 2017-04-12 艾克斯-马赛大学 纤维变性易感性il22ra2基因及其用途

Also Published As

Publication number Publication date
CN102325904A (zh) 2012-01-18
US20120135403A1 (en) 2012-05-31
CA2752802C (en) 2018-04-03
CN105907843A (zh) 2016-08-31
US9297044B2 (en) 2016-03-29
WO2010094740A1 (en) 2010-08-26
CN102325904B (zh) 2016-03-30
BRPI1008936B1 (pt) 2021-04-06
US20160230232A1 (en) 2016-08-11
JP2012524520A (ja) 2012-10-18
EP2398911B1 (en) 2017-10-18
JP2016047045A (ja) 2016-04-07
KR20120004971A (ko) 2012-01-13
KR101748679B1 (ko) 2017-07-03
CA2752802A1 (en) 2010-08-26
EP2221387A1 (en) 2010-08-25
EP2398911A1 (en) 2011-12-28
BRPI1008936A2 (pt) 2016-10-11
JP5837825B2 (ja) 2015-12-24

Similar Documents

Publication Publication Date Title
BRPI1008936B8 (pt) método in vitro para detectar pré-disposição para ou diagnóstico e/ou prognóstico de fibrose hepática ou cirrose ocorrendo em um indivíduo humano
MX2014005710A (es) Un metodo de cribado de farmaco y usos del mismo.
NO20083957L (no) DNA-konformasjon
BR112014031365A2 (pt) métodos de detectar doenças ou condições
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
WO2010099342A3 (en) Methods of detecting lung cancer
BR112013004673A8 (pt) biomarcadores e métodos de tratamento.
BR112013001752A2 (pt) método de detectar doenças ou condições usando células fagocídicas
GB2497007B (en) Methods of monitoring disease conditions by analysis of the full repertoire of the V-D junction or D-J junction sequences of an individual
WO2009085234A3 (en) Use of micro-rna as a biomarker of immunomodulatory drug activity
BR112013010015A2 (pt) aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
BR112013020773A2 (pt) "método para a detecção localizada in situ de rna, método para a determinação da presença e da localização de uma sequência genética, conjunto de sondas em cadeado, uso do conjunto de sondas, kit e método para a identificação de uma célula"
WO2014020502A3 (en) Markers associated with sensitivity to inhibitors of human double minute 2 (mdm2)
AR088827A1 (es) Metodos para tratar, diagnosticar, y monitorear la enfermedad de alzheimer
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
BR112012018394B8 (pt) método para detecção de uma sequência de ácido nucleico alvo e kit para detecção de uma sequência de ácido nucleico alvo
JP2014144959A5 (pt)
BR112012009262A2 (pt) ''método para inibir a proliferação de células de câncer positivo para ar em um indivíduo diagnosticado com,ou qual se suspeita que tenha cânce positivo para ar e método para identificar se um indivíduo é um candidato para tratamento com uma composiçâo
BRPI1013896A2 (pt) Célula de levedura, e, métodos para produzir um composto isoprenóide e para detectar em uma amostra biológica a presença ou ausência de uma célula microbiana geneticamente.
MX378733B (es) Métodos in vitro y composiciones para identificar y usarse en el tratamiento de lupus.
IN2014DN08537A (pt)
MX2013005796A (es) Metodos para detectar enfermedades o alteraciones neurodegenerativas.
BR112014010463A2 (pt) processo para detectar um ou mais sorotipos do vírus da dengue em uma amostra, kit para detecção da infecção por vírus da dengue, oligonucleotídeo isolado, pluralidade de oligonucleotídeos isolados, processo para diagnosticar ou confirmar o diagnóstico da presença ou ausência do vírus da dengue em um indivíduo, processo para detectar a presença ou ausência do vírus da dengue em uma amostra e uso de um primer ou sonda de ácido nucléico para preparar uma composição para diagnosticar ou confirmar a presença ou ausência do vírus da dengue em um indivíduo
WO2009114712A3 (en) Assays for diagnosing and evaluating treatment options for pompe disease

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA REC

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 06/04/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/02/2010, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 15A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.